Clinical trial · Observational
Real World Study on the Use of Cemiplimab in Adult Patients in UK
Real-world Evidence Study on the Early Use of Cemiplimab in the UK: REACT-CEMI (Real World Evidence of Advanced CSCC Treatment - With CEMIplimab)
NCT05493826CI-TRIAL-00068013REACT-CEMIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated in routine clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cutaneous Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- description
- Patients treated with cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- Overall response rate (ORR) within 12 months post initiation of cemiplimab
- timeFrame
- 12 months
- description
- ORR, defined as the proportion of patients who have a partial or complete response to cemiplimab based on an assessment according to routine practice, as documented in medical records
Secondary outcomes (23)
- measure
- ORR within 6 months post initiation of cemiplimab
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged \>=18 years at initiation of cemiplimab. * Patients treated with \>=1 dose of cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation according to routine practice. * Patients initiating treatment with cemiplimab in the UK between 2nd July 2019 and 30th November 2020. Exclusion Criteria: * Patients who are known to have opted out of participation in any research (as required for compliance with GDPR). * Patients participating in any form of investigative study (e.g., clinical trials) during the post-index observation period.
References
Publications (0)
Data not yet available
No reference posted for this study.